ArticleBMC gastroenterology2025
Independent effects of the hemoglobin-to-red blood cell distribution width ratio on 180-day mortality in critically ill patients with Gastrointestinal bleeding: analysis from the MIMIC-IV database.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between hemoglobin-to-red blood cell distribution width ratio trajectory patterns and in-hospital mortality in critically ill patients with cirrhosis: a retrospective cohort study based on MIMIC-IV and eICU-CRD.BMC medical informatics and decision making · 2026Article
- Lactate-to-albumin ratio as an independent predictor of mortality in critically ill patients with gastrointestinal bleeding: a retrospective cohort study.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal bleeding (GIB) is associated with high mortality rates among critically ill patients. The hemoglobin-to-red blood cell distribution width ratio (HRR) has recently emerged as a potential prognostic marker in various clinical settings. However, the association between HRR and prognosis in critically ill patients with GIB is unclear.
methodsWe conducted a retrospective cohort study using the MIMIC-IV database (version 2.2). Patients diagnosed with GIB were included based on predefined criteria. The HRR was calculated as the ratio of hemoglobin to red blood cell distribution width. Kaplan-Meier curves and multivariate Cox regression models assessed the association between HRR and 180-day mortality. Restricted cubic spline curves were employed to evaluate the nonlinear relationship between HRR and mortality. Additionally, a segmented regression model was constructed to determine the threshold effect in nonlinearity. Subgroup analyses were performed to assess the consistency of the relationship between HRR and 180-day mortality across different patient populations.
resultsA total of 2,346 patients met the inclusion criteria. Higher HRR was independently associated with reduced 180-day all-cause mortality (adjusted HR, 0.15; 95% CI, 0.07-0.31; P < 0.001). Non-linear associations were observed using restricted cubic splines (P for overall < 0.001, P for non-linearity = 0.002). When HRR was less than 0.81, each unit increase in HRR was associated with a 90% reduction in 180-day mortality among patients with GIB (HR, 0.10; 95% CI, 0.04-0.24; P < 0.001). Subgroup analyses demonstrated that the association between HRR and 180-day mortality was consistent across all subgroups.
conclusionHRR exhibits a significant nonlinear negative association with 180-day mortality in critically ill patients with GIB. This association was consistent across multiple subgroups, suggesting that HRR may serve as a simple and effective prognostic biomarker in patients with GIB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.